New blood test for Alzheimer’s

Australian and Japanese scientists have developed a simple blood test to help identify dementia.

The test identifies high levels of the protein, amyloid-β, a key cause of Alzheimer’s disease. Researchers hope that the test can be used to help identify Alzheimer’s early, partly in the hope of halting or preventing the disease. They also aim to use test results to recruit potential case studies prior to the irreversible brain damage that can be caused by the protein.

Scientists have long been searching for a way to beat dementia, and this test is seen as a solution to health researchers finding a way to manage Alzheimer’s and, hopefully, a cure.

Until now, the only ways to test for high amyloid-β levels were using positron-emission tomography to map the brain, by measuring the protein in spinal cord fluid or during an autopsy.

This test is the first to reliably identify people with the early stages of dementia. Most trials are conducted on people with existing symptoms of the disease. It is hoped that the test will lead to more reliable and effective medical trials.


Would you like to know if you have the early stages of Alzheimer’s? How far would you go to know?

Related articles:
Dementia stigma a cause for concern
Dementia drug leads to early death
Dementia vaccine breakthrough

Written by Leon Della Bosca

Leon Della Bosca has worked in publishing and media in one form or another for around 25 years. He's a voracious reader, word spinner and art, writing, design, painting, drawing, travel and photography enthusiast. You'll often find him roaming through galleries or exploring the streets of his beloved Melbourne and surrounding suburbs, sketchpad or notebook in hand, smiling.


Dementia stigma cause for concern

The stigma attached to dementia is the number one concern for people living with the disease.

Doctors want ban on drugs leading to dementia deaths

Geriatricians warn antipsychotics are causing early death for dementia patients.

Dementia: vaccine breakthrough

A breakthrough could see a vaccine targeting dementia produced within three to five years.